单次分割剂量增加提高前列腺癌根治性HDR近距离治疗后良性PSA反弹概率
研究纳入1999–2014年554例低/中危前列腺癌接受根治性HDR近距离治疗单药治疗且后续PSA检测≥3次的患者,比较四种分割方案(950 cGy×4次、1200 cGy×2次、1350 cGy×2次、1900 cGy×1次)与四种PSA反弹定义下的反弹发生率。中位随访3.7年,全队列3年PSA反弹率随定义阈值升高而降低;单次1900 cGy组PSA反弹>0.2 ng/mL的3年率最高(59.1%),且超过Phoenix生化失败定义(nadir+2 ng/mL)的反弹率也更高。
要点
- 单次1900 cGy组PSA反弹>0.2 ng/mL的3年率为59.1%,高于其他分割组(P=.002)。
- 单次1900 cGy相比多分次治疗,PSA反弹>0.2 ng/mL的风险比为1.786(P=.024)。
- 单次1900 cGy组超过Phoenix生化失败定义(nadir+2 ng/mL)的3年反弹率更高(P=.025)。
核心结论
- PSA反弹发生率随HDR单次分割剂量增加而升高。
- 了解治疗后PSA动力学有助于对潜在生化失败的管理决策。
研究设计与样本
- 回顾性分析1999–2014年554例低或中危前列腺癌接受根治性HDR近距离治疗单药治疗且后续PSA检测≥3次的患者。
- 采用四种分割方案:950 cGy×4次、1200 cGy×2次、1350 cGy×2次、1900 cGy×1次。
- 应用四种PSA反弹定义:较前次最低值升高≥0.2、≥0.5、≥1.0、≥2.0 ng/mL并随后回落至最低值。
主要发现
- 中位随访3.7年,全队列3年PSA反弹率分别为41.3%(nadir+0.2)、28.4%(nadir+0.5)、17.4%(nadir+1.0)、6.8%(nadir+2.0 ng/mL)。
- PSA反弹>0.2 ng/mL的3年率在950、1200、1350、1900 cGy/分次组分别为42.2%、32.1%、41.0%、59.1%(P=.002)。
- 单次1900 cGy组相比多分次治疗,PSA反弹>0.2 ng/mL的风险比为1.786(P=.024)。
- 单次1900 cGy组超过Phoenix生化失败定义(nadir+2 ng/mL)的1、2、3年反弹率分别为4.5%、18.7%、18.7%,高于其他剂量水平(P=.025)。
关键数值与推荐
- PSA反弹定义:较前次最低值升高≥0.2、≥0.5、≥1.0、≥2.0 ng/mL并随后回落至最低值。
- Phoenix生化失败定义:nadir+2 ng/mL。
临床怎么用
- 单次大分割HDR近距离治疗后PSA反弹概率较高,解读PSA升高时需考虑此良性现象以避免过早判定生化失败。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific antigen (PSA) bounce is a temporary elevation of the PSA level above a prior nadir. The purpose of this study was to determine whether the frequency of a PSA bounce following high-dose-rate (HDR) interstitial brachytherapy for the treatment of prostate cancer is associated with individual treatment fraction size. METHODS AND MATERIALS: Between 1999 and 2014, 554 patients underwent treatment of low- or intermediate-risk prostate cancer with definitive HDR brachytherapy as monotherapy and had ≥3 subsequent PSA measurements. Four different fraction sizes were used: 950 cGy × 4 fractions, 1200 cGy × 2 fractions, 1350 cGy × 2 fractions, 1900 cGy × 1 fraction. Four definitions of PSA bounce were applied: ≥0.2, ≥0.5, ≥1.0, and ≥2.0 ng/mL above the prior nadir with a subsequent return to the nadir. RESULTS: The median follow-up period was 3.7 years. The actuarial 3-year rate of PSA bounce for the entire cohort was 41.3%, 28.4%, 17.4%, and 6.8% for nadir +0.2, +0.5, +1.0, and +2.0 ng/mL, respectively. The 3-year rate of PSA bounce >0.2 ng/mL was 42.2%, 32.1%, 41.0%, and 59.1% for the 950-, 1200-, 1350-, and 1900-cGy/fraction levels, respectively (P=.002). The hazard ratio for bounce >0.2 ng/mL for patients receiving a single fraction of 1900 cGy compared with those receiving treatment in multiple fractions was 1.786 (P=.024). For patients treated with a single 1900-cGy fraction, the 1-, 2-, and 3-year rates of PSA bounce exceeding the Phoenix biochemical failure definition (nadir +2 ng/mL) were 4.5%, 18.7%, and 18.7%, respectively, higher than the rates for all other administered dose levels (P=.025). CONCLUSIONS: The incidence of PSA bounce increases with single-fraction HDR treatment. Knowledge of posttreatment PSA kinetics may aid in decision making regarding management of potential biochemical failures.
引用
- Hauck CR, Ye H, Chen PY, et al. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586946. doi:10.1016/j.ijrobp.2017.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。